Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&T

Total Tumor Volume on <sup>18</sup>F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with <sup>225</sup>Ac-PSMA-I&T

Background: PSMA-based alpha therapy using <sup>225</sup>Ac-PSMA-I&T provides treatment for metastatic castration-resistant prostate cancer (mCRPC), even after the failure of <sup>177</sup>Lu-PSMA radioligand therapy (RLT). In clinical routine, the total tumor volume (TTV...

Full description

Bibliographic Details
Main Authors: Lena M. Unterrainer, Leonie Beyer, Mathias J. Zacherl, Franz J. Gildehaus, Andrei Todica, Sophie C. Kunte, Adrien Holzgreve, Gabriel T. Sheikh, Annika Herlemann, Jozefina Casuscelli, Matthias Brendel, Nathalie L. Albert, Vera Wenter, Nina-Sophie Schmidt-Hegemann, Wolfgang G. Kunz, Clemens C. Cyran, Jens Ricke, Christian G. Stief, Peter Bartenstein, Harun Ilhan, Marcus Unterrainer
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Biomedicines
Subjects:
PSMA PET/CT
total tumor volume
<sup>225</sup>Ac-PSMA
mCRPC
Online Access:https://www.mdpi.com/2227-9059/10/5/946

Similar Items

Similar Items